Table 2.
Distribution of the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) SNP genotype in North American Caucasian patients with SSc and normal controls*
| MAF (%) | Allelic χ2 p value and OR | |||||
|---|---|---|---|---|---|---|
| SNP (minor allele) | Position (bp) | Controls (N=698) | SSc (N=1059) | pU | pFDR | OR (95% CI) |
| rs1234314 (G) | 171444015 | 41.3 | 45.8 | 0.01 | 0.019 | 1.20 (1.04 to 1.4) |
| rs2205960 (T) | 171458098 | 21.2 | 25.0 | 0.01 | 0.019 | 1.24 (1.1 to 1.5) |
| rs844644 (A) | 171476118 | 49.1 | 44.7 | 0.01 | 0.019 | 0.84 (0.7 to 0.97) |
| rs844648 (A) | 171490486 | 41.4 | 45.2 | 0.03 | 0.038 | 1.16 (1.01 to 1.3) |
| rs844665 (T) | 171515580 | 7.3 | 8.3 | 0.31 | 0.31 | 1.19 (0.9 to 1.5) |
*
Controls are used as reference for all comparisons. bp, base pairs; MAF, minor allele frequency; pFDR, corrected p values using Benjamini and Hochberg false discovery rate method; pU, uncorrected χ2 p values; SSc, systemic sclerosis; SNP, single nucleotide polymorphism.